(a) As used in this article:

(i) 'Opiate antagonist' means any device or medication approved by the United States food and drug administration for the treatment of an opiate related drug overdose;

(ii) 'Opiate related drug overdose' means a condition, including extreme physical illness, a decreased level of consciousness or respiratory depression resulting from the consumption or use of an opioid, or another substance with which an opioid was combined, that a reasonable person would believe to require medical assistance;

(iii) 'Pharmacist' means any person licensed under Wyoming statutes as a pharmacist and who is practicing within the scope of their license;

(iv) 'Practitioner' means any person licensed under Wyoming statutes as a physician, physician assistant or

advanced practice registered nurse and who is practicing within the scope of their license;

(v) 'Standing order' means an order transmitted electronically or in writing by a practitioner for a drug or device for a patient or multiple patients with whom no prescriber-patient relationship exists;

(vi) 'Entity' means any person as defined in W.S. 8-1-102(a)(vi), and includes the University of Wyoming and Wyoming community colleges, who employs persons who, in the course of their official duties or business, may encounter a person experiencing anaphylaxis or an opioid related drug overdose;

(vii) 'Opioid' or 'opiate' means an opiumlike compound that binds to one (1) or more of the major opioid receptors in the body;

(viii) 'Epinephrine' means a device or method that administers the drug epinephrine to a person experiencing anaphylaxis and includes epipens, nasal sprays or any other device or method under a different name used for emergency epinephrine delivery for the treatment of anaphylaxis and which device or method is approved by the United States food and drug administration.